cholecystitis and glp 1 The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study | Diabetology & Metabolic Syndrome GLP1-RAs and gallbladder diseases –

Einstein Foundation Berlin

Full AI Image Prompt: Create a clinical safety infographic titled GHK-Cu Safety Considerations by Route. Use a three-column matrix labeled Topical products, Wound-care study context, and Injectable or compounded preparations. Under topical products, include skin irritation, allergic reaction, and formulation sensitivity. Under wound-care study context, include study exclusions, copper or peptide sensitivity, and dressings or adhesives. Under injectable or compounded preparations, include limited human safety data, peptide-related impurities, aggregation risk, and immunogenicity risk. Use a calm medical style, white background, simple icons, and subtle copper-blue accents

Targets thin skin, visible veins, pigmentation, fine lines, and volume loss while improving skin thickness, tone, hydration, and youthful fullness

Accessed April 10, 2026.